Shots:

• TULIP 1 P-III trial with didn’t meet SRI4@12mos in moderate-to-severe SLE patients
• TULIP study includes two P-III trials TULIP 1 (N=460) in ratio (1:2:2) for 52 wks. administering of 150-300mg anifrolumab IV or PBO q4w; TULIP 2(N=373) in ratio (1:1) 300mg anifrolumab IV or PBO q4w- evaluating safety and efficacy
• Anifrolumab is also being assessed in P-III SLE long-term extension trial- a P-II trial using subcutaneous delivery in SLE and a P-II trial for lupus nephritis

Ref: AstraZeneca | Image:  Pharma Board room